[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857-524-2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 64, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 966228, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 42, "title": "CFO & COO", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 786196, "exercisedValue": 0, "unexercisedValue": 260}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 661890, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 54, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  McBride", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Hensley", "title": "Chief Legal Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott  Coleman Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7297, "open": 0.73, "dayLow": 0.7154, "dayHigh": 0.7499, "regularMarketPreviousClose": 0.7297, "regularMarketOpen": 0.73, "regularMarketDayLow": 0.7154, "regularMarketDayHigh": 0.7499, "payoutRatio": 0.0, "beta": -0.109, "forwardPE": -1.27, "volume": 408589, "regularMarketVolume": 408589, "averageVolume": 575183, "averageVolume10days": 1475410, "averageDailyVolume10Day": 1475410, "bid": 0.7133, "ask": 0.7698, "bidSize": 1, "askSize": 2, "marketCap": 38176432, "fiftyTwoWeekLow": 0.615, "fiftyTwoWeekHigh": 1.7, "priceToSalesTrailing12Months": 2.5449257, "fiftyDayAverage": 0.7002, "twoHundredDayAverage": 0.8171, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -75808560, "profitMargins": 0.0, "floatShares": 23433990, "sharesOutstanding": 51827900, "sharesShort": 4300761, "sharesShortPriorMonth": 3821839, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.083000004, "heldPercentInsiders": 0.45721, "heldPercentInstitutions": 0.25416002, "shortRatio": 9.4, "shortPercentOfFloat": 0.121400006, "impliedSharesOutstanding": 51827900, "bookValue": 0.136, "priceToBook": 5.416176, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -56222000, "trailingEps": -0.7, "forwardEps": -0.58, "enterpriseToRevenue": -5.054, "enterpriseToEbitda": 1.378, "52WeekChange": -0.093480945, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 0.7366, "targetHighPrice": 2.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.0, "targetMedianPrice": 2.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 121551000, "totalCashPerShare": 2.345, "ebitda": -55015000, "totalDebt": 7566000, "quickRatio": 2.282, "currentRatio": 2.323, "totalRevenue": 15001000, "debtToEquity": 107.031, "revenuePerShare": 0.289, "returnOnAssets": -0.31656998, "returnOnEquity": -2.77742, "grossProfits": 13021000, "freeCashflow": -13611625, "operatingCashflow": -13328000, "revenueGrowth": 2.43, "grossMargins": 0.86801004, "ebitdaMargins": 0.0, "operatingMargins": -1.77709, "financialCurrency": "USD", "symbol": "XLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "regularMarketChangePercent": 0.945588, "exchange": "NMS", "messageBoardId": "finmb_365333564", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 0.7366, "cryptoTradeable": false, "shortName": "Xilio Therapeutics, Inc.", "longName": "Xilio Therapeutics, Inc.", "postMarketChangePercent": -0.882434, "postMarketPrice": 0.7301, "postMarketChange": -0.00650001, "regularMarketChange": 0.00689995, "regularMarketDayRange": "0.7154 - 0.7499", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 575183, "fiftyTwoWeekLowChange": 0.12159997, "fiftyTwoWeekLowChangePercent": 0.19772352, "fiftyTwoWeekRange": "0.615 - 1.7", "fiftyTwoWeekHighChange": -0.96340007, "fiftyTwoWeekHighChangePercent": -0.5667059, "fiftyTwoWeekChangePercent": -9.348095, "earningsTimestampStart": 1754479858, "earningsTimestampEnd": 1754911858, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.7, "epsForward": -0.58, "fiftyDayAverageChange": 0.03639996, "fiftyDayAverageChangePercent": 0.05198509, "twoHundredDayAverageChange": -0.08050001, "twoHundredDayAverageChangePercent": -0.09851916, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-22", "corporateActions": [], "postMarketTime": 1757721481, "regularMarketTime": 1757707200, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634909400000, "displayName": "Xilio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]